Porth's Essentials of Pathophysiology, 4e

374

Infection and Immunity

U N I T 4

51. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004;351:760–768. 52. Centers for Disease Control and Prevention. Occupational HIV transmission among healthcare workers . 2011. Available at: http://www.cdc.gov/hiv/resources/factsheets/ hcwprev.htm. Accessed August 26, 2013. 53. Kuhar DT, Henderson DK, Struble KA, et al.; for the USPHS Writing Group. Updated U.S. Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875–892. 54. Brenner BG, Roger M, Routy JP, et al. Amplified transmission in early HIV infection. J Infect Dis. 2007;195:951–959. 55. Trecarichi EM, Tumbarello M, de Gaetano Donati K, et al. Partial protective effect of CCR5-delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther. 2006;3:22. 56. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep. 1992;41(RR-17):1–23. 57. Schneider E, Whitmore S, Glynn MK, et al. Revised surveillance case definitions for HIV infections among adults, adolescents, and children aged <18 months and for children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. 2008;57(RR-10),1–8. 58. Hecht FM, Wang L, Collier A. A multicenter observational study of potential benefits of initiating combination antiretroviral therapy during acute infection. J Infect Dis. 2006;194:725–733. 59. Rodriguez B, Sethi AK, Cheruvu VK. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498–1506. 60. Casaa C, Solomba S, Rauch A, et al. Host and viral genetic correlates of clinical definitions of HIV-1 progression. PLoS One. 2010;5(6):e11079. 61. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of HIV associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5–S14. 62. UNAIDS. Frequently asked questions about tuberculosis . 2006. Available at: http://data.unaids.org/pub/factsheet/2006/tb_ hiv_ qa.pdf. Accessed August 26, 2013. 63. Wilcox CM. Gastrointestinal manifestations of AIDS. Nutr Clin Pract. 2004;19:356–364. 64. Antinori A, Arendt G, Becker JT. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799. 65. Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev. 2006;19(3):CD005420. 66. Berger JR, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. 2006;28:299–305. 67. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19:446–451. 68. Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–1038. 69. De Vuyst H, Franceschi S. Human papillomavirus vaccines in HIV- positive men and women. Curr Opin Oncol. 2007;19:470–475. 70. Polsky B, Kotler D, Steinhart C. Treatment guidelines for HIV- associated wasting. HIV Clin Trials. 2004;5:50–61. 71. Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep. 2005;2:132–139. 72. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184.

73. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis. 2004;174:1–10. 74. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41:590–597. 75. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62. 76. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr. 2004;37(suppl 1):S30–S35. 77. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651–681. 78. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral rapid HIV-1/2 test experience with four CDC studies. AIDS. 2006;20:1655–1660. 79. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated February 12, 2013; 1–161. Available at: http:// www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed August 26, 2013. 80. Maplanka C. AIDS: is there an answer to the global pandemic? The immune system in HIV infection and control. Viral Immunol. 2007;20:331–342. 81. McIntyre J. Managing pregnant patients. In: Dolin R, Masur H, Saag M, eds. AIDS Therapy . 3rd ed. London, UK: Churchill Livingston; 2008:595–597. 82. Yogev R, Chadwick EG. Acquired immunodeficiency syndrome (human immunodeficiency virus). In: Behrman RE, Kliegman RM, Jenson HB, et al., eds. Nelson Textbook of Pediatrics . 18th ed. Philadelphia, PA: Saunders Elsevier; 2007:1427–1443. 83. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal- infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;33:1173–1180. 84. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States . 2012. Available at: http:// AIDSinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed August 26, 2013. 85. Centers for Disease Control and Prevention, the National Institutes of Health, the HIV Medicine Association of Infectious Diseases Society of America, the Pediatric Infectious Disease Society, and the American Academy of Pediatrics. Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children . 2009. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_ pediatrics.pdf. Accessed August 26, 2013.

Porth Essentials Resources Explore these additional resources to enhance learning for this chapter: •  NCLEX-Style Questions and Other Resources

on

, http://thePoint.lww.com/PorthEssentials4e

• Study Guide for Essentials of Pathophysiology • Concepts in Action Animations • Adaptive Learning | Powered by PrepU, http://thepoint.lww.com/ prepu